drugset / Trial / NCT04405921
Hydroxychloroquine, Azithromycin in the Treatment of Covid-19
RandomizedParallel-groupDouble-blindTreatment
Summary
This study investigates the efficay and tolerance of 5-days course of hydroxychloroquine or hydroxychloroquine and azithromycin of patients with COVID-19 infection. The investigators will undertake a randomized, double-blind, controlled Trial in the region of Sousse Tunisia
Timeline
- Start
- 2020-07
- Primary completion
- 2020-12
- Completion
- 2021-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 250 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 200 mg | Oral |